...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Zack's $5 Price target...

I don't think I'm alone in thinking that John Vandermosten's $5 PT is low, as in incredibly, amazingly, stupefyingly low.

Crestor's top revenue year was about $6.6 billion:

https://www.statista.com/statistics/266552/astrazenecas-crestor-revenue/

Over 14.5 years Lipitor brought in $125 billion, that's an average of over $8.6 billion dollars a year and it was at a time the world's highest revenue generating drug. 

http://www.crainsnewyork.com/article/20111228/HEALTH_CARE/111229902/lipitor-becomes-worlds-top-selling-drug

Obviously we don't know yet if Apabetalone can attain the sales levels of either of those two drugs, but I do think its possible....Diabetes, Kidney, Alzheimer's....just those 3 alone, I have to think its  at least possible if those 3 indications are shown to have proven benefit from Apabetalone.

$5 per share CDN would give us a MC of only about $1 billion CDN and that's allowing for further dilution up to about 200 million shares outstanding with the existing (no consolidation) structure.

$2 or $3 billion USD seems far more reasonable to me in terms of pipeline value.  But of course its all a moot point right now at $3 and change.  If we get to $5 and if the demand is there  for shares at that price, that will speak volumes...and I hope it happens obviously. 

Obviously if we get to $5 and buyers are willing to pay that price, then that would mean those buyers don't  think  much of the $5 PT....

All hypothetical at this point (moot, not mute) and hopefully we get to see what happens at $5.

 

Share
New Message
Please login to post a reply